Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial (Q44094790)

29 November 2017

title

Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial (English)

1 reference

triple-negative breast cancer

29 November 2017

0 references

1 reference

1 reference

Hope S Rugo

1 reference

29 November 2017

Denise A Yardley

1 reference

29 November 2017

Adam Brufsky

1 reference

29 November 2017

Vicente Valero

1 reference

29 November 2017

Beatrice Tiangco

1 reference

29 November 2017

Shaker Dakhil

1 reference

29 November 2017

Arija Brize

1 reference

29 November 2017

Ragene Rivera

1 reference

29 November 2017

Anja Duenne

1 reference

29 November 2017

Naima Bousfoul

1 reference

29 November 2017

language of work or name

English

0 references

publication date

14 March 2012

1 reference

Breast Cancer Research and Treatment

29 November 2017

published in

1 reference

29 November 2017

volume

133

1 reference

29 November 2017

1 reference

29 November 2017

page(s)

1067-1075

1 reference

Triple-negative breast cancer--current status and future directions

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Triple-negative breast cancer: clinical features and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Triple-negative breast cancer: role of antiangiogenic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

What is triple-negative breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2008-6

10.1007/S10549-012-2008-6

21 January 2018

Identifiers

DOI

1 reference

29 November 2017

1 reference